Comparative Pharmacology
Head-to-head clinical analysis: TAVIST 1 versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAVIST 1 versus XYZAL.
TAVIST-1 vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
1.34 mg orally twice daily; maximum 8.04 mg/day.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine